Aardvark Therapeutics, Inc. (AARD) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.87

From 52W high−76.36%

Volume129798.00

Market cap$81.85M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$3.87

From 52W high

−76.36%

Volume

129798.00

Market cap

$81.85M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.1x

P/E (TTM)

—

RSI (14)

29.5

MomentumView details →

1D Return

−1.06%

YTD Return

−70.91%

SummaryUpdated Jun 1, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in San Diego, California. The company specializes in developing innovative small-molecule therapeutics that target the body's natural homeostatic pathways to treat metabolic diseases. Since its incorporation, Aardvark has focused on addressing rare metabolic disorders through a novel approach of activating bitter taste receptors in the gastrointestinal tract, representing a unique therapeutic strategy in the biotechnology sector.

Ask drillr about Aardvark Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−93.44%

ROA (TTM)

−85.80%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−53.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−82.89%

MomentumView details →

1D Return

−1.06%

YTD Return

−70.91%

1Y Return

−68.89%

RSI (14)

29.5

vs 50D SMA

−31.35%

vs 200D SMA

−44.29%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

12.63x

Quick Ratio

12.63x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.66

EPS Surprise

24.52%

Beats (12Q)

3/12

Next Q EPS Est

−$0.72

Avg Surprise (4Q)

5.34%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−69.89M

Op. CF (TTM)

−69.41M

Next earningsNov 12, 2026 →

Latest newsMore news →

A class action lawsuit alleging federal securities law violations was filed against Aardvark Therapeutics, Inc.8d ago

Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. breached their fiduciary duties to shareholders.26d ago

Similar companies

Tenaya Therapeutics, Inc.TNYA Equillium, Inc.EQ Neonc Technologies Holdings, Inc.NTHI Corbus Pharmaceuticals Holdings, Inc.CRBP China Regenerative Medicine International Limited08158.HK Rallybio CorporationRLYB Find similar companies →

Latest newsMore news →

A class action lawsuit alleging federal securities law violations was filed against Aardvark Therapeutics, Inc.8d ago Kuehn Law, PLLC announced it is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. breached their fiduciary duties to shareholders.26d ago Moore Law PLLC announced it is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. on behalf of shareholders.39d ago